- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- Science Education Progress
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Administration to Split FDA?
The Associated Press reports that drug makers are quietly hopeful that recent appointments signal an agency-level bifurcation between food safety and drug safety responsibilities:
Drug industry advocates are quietly allying with some of their longtime critics pushing to split the Food and Drug Administration into two agencies, one for food safety and one for medical products.
President Barack Obama bolstered hopes for a breakup last Saturday when he named two public health specialists to the agency’s top positions and appointed an advisory group to reassess the nation’s decades-old food safety laws.
Drug executives see a chance to speed up drug approvals that have lagged amid a drought of new products, provided their regulator is no longer distracted by high-profile food-safety breakdowns.
Other ideas have also been floated in the past for the creation of an over-arching food safety agency. But if a split is in the works, there have to be sufficient resources ready to tackle the problems FDA will still face, which include missing review deadlines on 20 percent of 2008 drug applications (according to the AP), a problem that could be compounded by workforce issues. As Virginia Cox points out in her chapter on FDA in Change for America: “Almost 50 percent of [FDA] managers and supervisors are eligible for retirement in the next five years.”
Comments on this article


